CGEN

Rating neutralAI Memo

Compugen

As of 2026-05-27/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

low

Horizon

—

Key catalyst

MAIA-ovarian interim readout remains the main company-controlled inflection • 2027-03-31

Expected move: +30%

Biggest risk

The bear case is that near-term fundamentals are still light: revenue was only about $2.2 million, losses continue, and the stock remains dependent on long-dated clinical and partner milestones that can slip or disappoint. If burn accelerates, dilution risk can reappear despite the current runway.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The bullish case is that Compugen has enough cash to fund the current plan into 2029, no debt, and multiple optionality layers: MAIA-ovarian readout in Q1 2027, plus partner-backed rilvegostomig and GS-0321 programs that could generate milestones or royalties if development continues to progress.

Research note

Recommendation

neutral

Confidence

low

As of

2026-05-27

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 print confirms runway but not near-term growth
Partner programs keep royalty and milestone optionality alive
No-debt balance sheet reduces near-term dilution pressure

BearKey bullets

Even with runway into 2029, a faster-than-expected rise in clinical spend could bring dilution risk back sooner than expected.
MAIA-ovarian enrollment or interim-analysis timing could slip past Q1 2027, pushing out the main company-controlled inflection point.
Partner upside from AstraZeneca and Gilead is meaningful but largely outside Compugen's direct control.

WatchKey bullets

MAIA-ovarian interim readout remains the main company-controlled inflection

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=45%)

Bull/Bear spread: +99% / -31%

Vs latest close: Bull +99% · Base +30% · Bear -31%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $4 (p=45%)Bear Target: $2 (p=30%)

Commentary

Headline tone around the May 18 release was mildly positive, but the only primary evidence here is the company 6-K and the packet does not include reliable analyst revisions or a durable post-print price series. That keeps this in monitoring mode rather than a high-conviction rerating.

As of 2026-05-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 print confirms runway but not near-term growth
Partner programs keep royalty and milestone optionality alive
No-debt balance sheet reduces near-term dilution pressure

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$4 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Price $3 as of 2026-05-27

Nearest Scenario: Base (∆ 30%)

Targets vs latest close: Bull +99% · Base +30% · Bear -31%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
MAIA-ovarian interim readout remains the main company-controlled inflection
Compugen said COM701 MAIA-ovarian is actively enrolling across sites in the U.S., Israel, and France and remains on track for an interim analysis by Q1 2027, which is still the clearest binary value event in the story [#6K-2026-05-18].
Prob 70.00% • Move 35.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Q1 2026 print confirms runway but not near-term growth
2026-05-18
The May 18, 2026 6-K showed flat revenue of about $2.2 million versus $2.3 million a year ago, net loss of about $7.7 million or $0.08 per share, higher R&D tied mainly to MAIA-ovarian clinical spend, and cash/cash equivalents plus deposits and marketable securities of about $134.9 million with runway into 2029 [#6K-2026-05-18].
Prob 60% • Move 10% • Priced-in 55%

Long-term Catalysts

Months to a year

Partner programs keep royalty and milestone optionality alive
2026-12-31
The same filing said AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and that Gilead-partnered GS-0321 continues to progress in Phase 1, while Compugen reiterated roughly $1 billion in potential milestones plus royalties from the two partnerships [#6K-2026-05-18].
Prob 45% • Move 20% • Priced-in 30%
No-debt balance sheet reduces near-term dilution pressure
2026-12-31
Compugen reported no debt and a cash runway into 2029 based on current plans, which meaningfully lowers immediate financing risk even though future burn could still re-open dilution concerns if clinical spending rises [#6K-2026-05-18].
Prob 80% • Move 12% • Priced-in 70%

Risks

Even with runway into 2029, a faster-than-expected rise in clinical spend could bring dilution risk back sooner than expected.
MAIA-ovarian enrollment or interim-analysis timing could slip past Q1 2027, pushing out the main company-controlled inflection point.
Partner upside from AstraZeneca and Gilead is meaningful but largely outside Compugen's direct control.
The company still has a very small revenue base, so operating results are not yet self-sustaining and losses remain.

Peers

Symbol	Summary
ALXO	ALX Oncology is a similarly sized, clinical-stage oncology biotech where valuation is also driven by trial execution, partner optionality, and financing durability more than current product revenue.
FATE	Fate Therapeutics is another small-cap biotech with a catalyst-heavy profile, though its platform and program mix are different enough that it should be treated as a loose peer rather than a clean operating comp.
EDIT	Editas Medicine is comparable mainly on size and event-driven biotech dynamics; the science and commercialization path are different, so it is useful for risk appetite context more than for direct operating comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-27

AI Stock Memo: CGEN - Compugen - RankAlpha